TORONTO, Nov 5 (Reuters) - Transition Therapeutics Inc (TTH.TO) said on Monday it will cancel its partnership agreement with Novo Nordisk AS (NOVOb.CO) on its diabetes program and take back all its rights held by Novo after the two companies failed to come to terms on a licensing agreement.
Transition said it would continue discussions with other interested parties concerning the diabetes programs.
($1=$0.94 Canadian)
OTTAWA (Reuters) - Research In Motion posted a big jump in profit and issued an even stronger outlook on Thursday, as sturdy demand from holiday shoppers helped the BlackBerry maker fend off the competition.
If the U.S. is serious about creating jobs it should invest in aviation programs, says the chief of the Aerospace Industries Association. Just don't call it a bailout. Full Article
"I told Michelle when we got here that in six months my poll numbers will start crashing," says President Obama. He's not worried -- yet. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
